Insulet (PODD)
(Delayed Data from NSDQ)
$236.59 USD
+7.46 (3.26%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $237.00 +0.41 (0.17%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$236.59 USD
+7.46 (3.26%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $237.00 +0.41 (0.17%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth D Momentum C VGM
Zacks News
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and a favorable liquidity structure.
Tandem Diabetes (TNDM) Launches Dexcom G7 Integrated t:slim X2
by Zacks Equity Research
Tandem Diabetes' (TNDM) t:slim X2 is the first AID system in the world to feature Dexcom's most advanced CGM technology.
Omnicell's (OMCL) Global Expansion Strong, Macro Issues Ail
by Zacks Equity Research
Omnicell (OMCL) accelerates a shift to cloud-based solutions and tech-enabled services through the launches of Inventory Optimization Service and Central Pharmacy Dispensing Services.
Neogen (NEOG) to Offer Biosecurity Products With New Pact
by Zacks Equity Research
Neogen will be able to highlight its biosecurity and horse health products, like the COMPANION range of cleansers and disinfection solutions, through the latest collaboration.
Here's Why You Should Retain Align Technology (ALGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) on global expansion and strategic alliance.
Teleflex (TFX) Signs Peripheral Access Purchasing Deal With PINC
by Zacks Equity Research
Teleflex (TFX) secures the Peripheral Access purchasing agreement with Premier, Inc.
Integra Gains From New Product Launches, Mounting Costs Ail
by Zacks Equity Research
Integra expands the international reach of the CUSA platform and registers DuraGen, DuraSeal, Mayfield and Duo LED lighting in the EMEA and Latin America.
Boston Scientific (BSX) Gains From Global Expansion, FX Woe Ails
by Zacks Equity Research
Boston Scientific's (BSX) Endoscopy business within MedSurg benefits from strong worldwide demand for its broad range of GI and pulmonary treatment options.
Henry Schein's (HSIC) Zahn Dental and Myerson Enter New Deal
by Zacks Equity Research
Henry Schein's (HSIC) dental laboratory business, Zahn Dental, is set to exclusively distribute Myerson's New Trusana 3D Premium Denture System.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Charles River's (CRL) share price is likely to grow, backed by the strength of the DSA segment.
The Zacks Analyst Blog Highlights NVIDIA, Vertiv Holdings, Copart, Insulet and Constellation Energy
by Zacks Equity Research
NVIDIA, Vertiv Holdings, Copart, Insulet and Constellation Energy are included in this Analyst Blog.
Zacks.com featured highlights Insulet, W.R. Berkley, Invitation Home and VICI Properties
by Zacks Equity Research
Insulet, W.R. Berkley, Invitation Home and VICI Properties have been highlighted in this Screen of The Week article.
Exact Sciences (EXAS) Up 35.4% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS), driven by growth in Screening and Precision Oncology segments.
Top 5 Momentum Picks for December After Rejuvenated November
by Nalak Das
Five momentum stocks for December are: NVDA, VRT, CPRT, CEG, PODD.
Thermo Fisher (TMO) Advances Health Equity via New Partnership
by Zacks Equity Research
Thermo Fisher (TMO) announces a collaboration with Project HOPE to improve health outcomes by enabling expanded access to HIV testing and support services in Nigeria.
4 Best Stocks to Invest in for Solid Earnings Growth
by Tirthankar Chakraborty
Invest in stocks such as Insulet (PODD), W.R. Berkley (WRB), Invitation Home (INVH) and VICI Properties (VICI) for superb earnings growth.
BiomX (PHGE) Reports Positive Pulmonary Infection Treatment Data
by Zacks Equity Research
BiomX's (PHGE) BX004 showcases an impressive 14% conversion to a negative P. aeruginosa sputum culture at the end of treatment.
Neogen (NEOG) Unveils New Assay for Walnut Allergens Detection
by Zacks Equity Research
Neogen's (NEOG) Veratox VIP for Walnut allergy test displays robust performance across sample types while keeping the Veratox product line's simple testing approach.
CVS Health's (CVS) Digital Focus Aids Growth, Macro Issues Ail
by Zacks Equity Research
CVS Health's (CVS) Health Care Benefits segment demonstrates value to consumers and clients by successfully managing drug cost trends and bringing innovative clinical solutions to the market.
Walgreens (WBA) Launches Rx Savings Finder Digital Tool
by Zacks Equity Research
Walgreens (WBA) introduces Rx Savings Finder to help patients save on prescription medications.
Thermo Fisher (TMO) Extends Partnership With Flagship Pioneering
by Zacks Equity Research
Thermo Fisher's (TMO) in-depth knowledge of the life sciences sector will be combined with Flagship Pioneering to create revolutionary capabilities for the ecosystem.
Charles River (CRL) Gains on Price & Volume Growth Amid FX Woe
by Zacks Equity Research
At present, Charles River (CRL) is the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.
Inspira (IINN) Expands in Life Support Space With New Deal
by Zacks Equity Research
According to Inspira (IINN), the integration of its technology to oxygenate blood combined with Ennocure's infection prevention solutions is likely to help improve patient outcomes in ICUs.
Penumbra (PEN) Enrolls First Patient in Landmark STORM-PE Trial
by Zacks Equity Research
Penumbra (PEN) achieves an important milestone by enrolling the first patient in STORM-PE RCT.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) on the strength of the base business.